CSL Limited (ASX:CSL – Get Free Report) insider Brian McNamee acquired 433 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was bought at an average cost of A$151.56 per share, with a total value of A$65,625.05.
CSL Stock Performance
The company has a market capitalization of $77.43 billion, a P/E ratio of 28.02, a price-to-earnings-growth ratio of 1.29 and a beta of 0.32. The company has a debt-to-equity ratio of 64.46, a quick ratio of 1.68 and a current ratio of 1.86.
CSL Dividend Announcement
The company also recently disclosed a Interim dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Wednesday, April 8th will be paid a $1.837 dividend. This represents a dividend yield of 121.0%. The ex-dividend date is Monday, March 9th. CSL’s dividend payout ratio (DPR) is presently 50.38%.
About CSL
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology.
Featured Articles
- Five stocks we like better than CSL
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- Gold $5,000: The 2026 Gold & Silver Summit is LIVE March 4
- How a Family Trust May Be Able To Help Preserve Your Wealth
- This makes me furious
- Elon Musk: This Could Turn $100 into $100,000
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.
